Regulus Therapeutics (NASDAQ:RGLS) Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Regulus Therapeutics (NASDAQ:RGLS) from a buy rating to a hold rating in a report published on Wednesday morning, Zacks.com reports.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

A number of other analysts also recently issued reports on RGLS. Wedbush reiterated a hold rating and set a $1.00 price target on shares of Regulus Therapeutics in a research report on Thursday, May 16th. Wells Fargo & Co set a $162.00 price target on Jazz Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, March 19th. Finally, ValuEngine upgraded WPP from a sell rating to a hold rating in a research report on Wednesday, June 19th. One analyst has rated the stock with a sell rating and four have issued a hold rating to the company’s stock. Regulus Therapeutics currently has an average rating of Hold and a consensus target price of $1.25.

Shares of RGLS opened at $1.26 on Wednesday. The firm’s 50-day simple moving average is $1.18. Regulus Therapeutics has a 12-month low of $0.80 and a 12-month high of $4.08.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.15) by $0.84. The firm had revenue of $6.78 million during the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative return on equity of 186,717.70% and a negative net margin of 526.10%. On average, sell-side analysts forecast that Regulus Therapeutics will post -2.13 earnings per share for the current year.

In other news, major shareholder Peter J. Barris acquired 1,136,704 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The shares were bought at an average cost of $1.08 per share, with a total value of $1,227,640.32. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Joseph P. Hagan acquired 33,194 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The shares were purchased at an average cost of $1.08 per share, for a total transaction of $35,849.52. Following the completion of the acquisition, the chief executive officer now owns 64,542 shares in the company, valued at approximately $69,705.36. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 1,199,528 shares of company stock valued at $1,295,490 and have sold 66,979 shares valued at $85,896. Company insiders own 10.70% of the company’s stock.

An institutional investor recently raised its position in Regulus Therapeutics stock. Wedbush Securities Inc. lifted its position in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) by 32.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,489 shares of the biopharmaceutical company’s stock after buying an additional 10,751 shares during the period. Wedbush Securities Inc. owned about 0.40% of Regulus Therapeutics worth $44,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.94% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Featured Story: How to Use the New Google Finance Tool

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.